Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NITE
Previous Symbol
CUSIPN/A
Phone646-522-8445
Debt
Debt-to-Equity RatioN/A
Current Ratio7.67
Quick Ratio7.67
Price-To-Earnings
Trailing P/E Ratio-7.14
Forward P/E Ratio-8.43
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.48 per share
Price / Book2.60
Profitability
EPS (Most Recent Fiscal Year)($1.63)
Net Income$-29,680,000.00
Net MarginsN/A
Return on Equity-38.68%
Return on Assets-35.08%
Miscellaneous
Employees23
Outstanding Shares28,100,000
Market Cap$325.68 million
OptionableNot Optionable
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
How were Nightstar Therapeutics' earnings last quarter?
Nightstar Therapeutics PLC (NASDAQ:NITE) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History.
When is Nightstar Therapeutics' next earnings date?
What price target have analysts set for NITE?
8 equities research analysts have issued 12-month price targets for Nightstar Therapeutics' stock. Their predictions range from $24.00 to $41.00. On average, they expect Nightstar Therapeutics' share price to reach $34.4286 in the next year. This suggests a possible upside of 195.8% from the stock's current price. View Analyst Price Targets for Nightstar Therapeutics.
What is the consensus analysts' recommendation for Nightstar Therapeutics?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (12/12/2018)
- 2. Mizuho analysts commented, "We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock." (9/25/2018)
Has Nightstar Therapeutics been receiving favorable news coverage?
Media headlines about NITE stock have been trending somewhat positive on Saturday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nightstar Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Orchard Therapeutics (ORTX), Autolus Therapeutics (AUTL), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), DBV TECHNOLOGIE/S (DBVT), Solid Biosciences (SLDB), Cellectis (CLLS), Acorda Therapeutics (ACOR), Heska (HSKA) and Vericel (VCEL).
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 61)
- Mr. Senthil Sundaram, Chief Financial Officer (Age 40)
- Dr. Gregory Robinson, Chief Scientific Officer (Age 59)
- Brian Luque, Sr. Mang. of Investor Relations
- Mr. Bryan Yoon, Gen. Counsel & Sec. (Age 40)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
Who are Nightstar Therapeutics' major shareholders?
Nightstar Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Redmile Group LLC (7.41%), Point72 Asset Management L.P. (5.43%), Tekla Capital Management LLC (0.53%), Renaissance Technologies LLC (0.29%), Monashee Investment Management LLC (0.25%) and Citadel Advisors LLC (0.24%).
Which institutional investors are selling Nightstar Therapeutics stock?
NITE stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC.
Which institutional investors are buying Nightstar Therapeutics stock?
NITE stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, Tekla Capital Management LLC, Renaissance Technologies LLC, Monashee Investment Management LLC, Citadel Advisors LLC, Marshall Wace LLP and JPMorgan Chase & Co..
How do I buy shares of Nightstar Therapeutics?
Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of NITE stock can currently be purchased for approximately $11.64.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $325.68 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe.
What is Nightstar Therapeutics' official website?
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
